LAWRENCE, Mass., Dec. 7, 2017 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading medical technology company
focused on advancing renal care, today announced new results in
Hemodialysis International, demonstrating its remote patient
management system, Nx2me Connected Health, reduces home
hemodialysis technique failure, or conversion to in-center
hemodialysis, by 29%.1
In the study, outcomes among 606 Nx2me users and contemporary
matched controls were compared.1 Nx2me users comprised
both patients already established on home hemodialysis with the
NxStage System One and new home hemodialysis patients. In patients
who began to use Nx2me within 3 months after initiating home
hemodialysis, technique failure was reduced by 34%, relative to
matched controls.1 Additionally, patients who began to
use Nx2me during home hemodialysis training were 61% more likely to
complete training and did so in 7 fewer days, relative to matched
controls.1
A key component of the Nx2me platform is the Nx2me
iPad® app, which is designed to increase patients' ease
of use of home therapy by capturing treatment data and wirelessly
sending it to their center after each treatment, thereby reducing
the need for paper flow sheets. Dialysis center staff can access
the treatment data, sent through a secured and encrypted web
server, using the Nx2me Clinician Portal. The timely receipt of
electronic flowsheets from the Nx2me app allows for early
intervention to help reduce patient complications and
hospitalizations. In addition, Nx2me integrates with center EMR
systems to provide clinicians with treatment and billing
information.
"Nx2me provides the tools to support and proactively engage with
patients," said, Eric Weinhandl,
Clinical Epidemiologist and Statistician, NxStage Medical, Inc.
"Nx2me enhances dialysis care for both patients and center staff,
and the performance data continue to demonstrate improved training
graduation and patient retention, which both help to grow home
hemodialysis."
For more information about Nx2me and home hemodialysis with the
NxStage System One, please visit www.NxStage.com.
The NxStage System One is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if needed.
Patients should consult with their doctor to understand the risks
and responsibilities of home and/or more frequent hemodialysis
using the NxStage System One. Additionally, the reported benefits
of home and/or more frequent hemodialysis may not be experienced by
all patients.
The Nx2me Connected Health System is not intended to provide
time sensitive data or alarms and does not control the System One
Cycler. The system may not be used as a substitute for direct
medical intervention or emergency care.
About the NxStage System One
The NxStage System One
is the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis, home nocturnal
hemodialysis and solo home hemodialysis. Its simplicity and
revolutionary size (just over a foot tall) are intended to allow
convenient use in patients' homes and give patients the freedom to
travel with their therapy. When combined with the NxStage PureFlow
SL Dialysis Preparation System, patients are able to further
simplify, using ordinary tap water to create dialysis fluid on
demand. Unlike conventional hemodialysis systems, the System One
requires no special infrastructure to operate. Under the guidance
of their physician, patients can use the NxStage System One, with
their trained partners (or for patients prescribed to receive solo
dialysis, alone), where, how and when it best meets their needs,
including while they are sleeping - at home or on vacation and at a
medically appropriate treatment frequency. In addition, NxStage's
Nx2me Connected Health platform collects important NxStage System
One and patient information for flexible viewing, monitoring and
reporting that may improve patient management and patient
retention, as well as simplify alternative site care.
www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc.
(Nasdaq: NXTM) is a leading medical technology company,
headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics committed to the development of
innovative care delivery models for patients with ESRD. For more
information on NxStage and its products and services, please visit
the Company's websites at www.nxstage.com and
www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2017. NxStage is under
no obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
References: 1. Weinhandl ED, Collins AJ. Relative risk of
home hemodialysis attrition in patients using a telehealth
platform. Hemodial Int. 2017.
http://onlinelibrary.wiley.com/doi/10.1111/hdi.12621/full
View original content with
multimedia:http://www.prnewswire.com/news-releases/nx2me-connected-health-improves-home-hemodialysis-retention-300568624.html
SOURCE NxStage Medical, Inc.